LENALIDOMIDE SPC 25 mg 21 Capsule

Product Overview

LENALIDOMIDE SPC 25 mg capsules are a prescription medication primarily used in oncology to treat specific blood cancers and disorders. As an immunomodulatory agent, it plays a crucial role in managing conditions such as multiple myeloma, certain types of myelodysplastic syndromes (MDS), and mantle cell lymphoma (MCL).

This medication works by modifying the body's immune system, exhibiting anti-angiogenic (inhibiting new blood vessel formation) and anti-neoplastic (inhibiting tumor growth) properties. It is a potent therapy that must be used under strict medical supervision due to its complex mechanism of action and significant safety profile.

Benefits of Use

• Helps to slow the progression of specific blood cancers and hematological malignancies.
• Improves disease outcomes and management for eligible patients with multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.
• Acts through multiple pathways including immunomodulation, anti-angiogenesis, and direct anti-tumor effects.

How to Use

1. LENALIDOMIDE SPC 25 mg capsules are for oral administration only.
2. Always take this medication exactly as prescribed by your physician. Do not alter the dose or duration of treatment without consulting your doctor.
3. Swallow the capsule whole with a glass of water, with or without food. Do not open, break, or chew the capsules.
4. Typically, the medication is taken once daily, but your doctor will provide specific instructions based on your condition and treatment regimen.
5. It is crucial to adhere to all monitoring requirements and follow-up appointments scheduled by your healthcare provider.

Caution & Warnings

• Teratogenicity Risk: Lenalidomide is highly teratogenic (causes severe birth defects). It is absolutely contraindicated in pregnant women. Strict contraception must be used by both male and female patients during treatment and for a specified period after. Do not handle capsules if pregnant or suspect you might be.
• Thromboembolism: There is an increased risk of venous and arterial thromboembolism (blood clots) during treatment. Discuss any history of blood clots or risk factors with your doctor.
• Myelosuppression: May cause severe myelosuppression, including neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood tests are necessary to monitor blood counts.
• Second Primary Malignancies: An increased risk of developing other types of cancer has been observed in some patients treated with lenalidomide.
• Liver and Kidney Function: Monitor liver and kidney function regularly, as dose adjustments may be required in patients with renal impairment.
• Allergic Reactions: Seek immediate medical attention if you experience signs of a severe allergic reaction (e.g., rash, swelling, difficulty breathing).
• Strict Management Programs: Due to its serious risks, lenalidomide is typically dispensed under strict risk management programs (e.g., REMS in the US, similar programs internationally). Ensure you understand and comply with all program requirements.

Ingredients

Active Ingredient: Lenalidomide 25 mg.

(Excipients typically include microcrystalline cellulose, magnesium stearate, lactose anhydrous, and gelatin capsule components. Specific excipients vary by manufacturer and are not detailed without explicit data.)

Product Details

• Drug Type: Prescription Only Medicine (POM).
• Form: Oral Capsules.
• Strength: 25 mg per capsule.
• Package Size: 21 Capsules per pack.
• Storage: Store below 30°C. Protect from moisture and light.